昭衍新药（06127）今日盘中大跌5.10%，引发市场关注。
消息面上，瑞银集团发布最新研究报告，将昭衍新药的投资评级从"买入"下调至"中性"，这可能是导致股价大幅下跌的主要原因。尽管瑞银将目标价从12.6港元上调至14.3港元，但投资者似乎更关注评级的下调。
瑞银报告指出，昭衍新药去年业绩大致符合预期，但收入和纯利均出现下滑，分别同比下降15.1%和81.3%。该行认为市场已基本消化了过去几个季度的复苏，但也注意到去年第四季度新订单再次转弱。此外，瑞银将公司未来三年的每股盈利预测分别下调1%、15%和26%，反映出对公司短期增长前景的担忧。值得注意的是，报告还提到今年第一季度中国生物制药行业资金疲软可能对昭衍新药构成阻力，这进一步加剧了投资者的忧虑情绪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.